Log In
Print
BCIQ
Print
Print this Print this
 

APO010

  Manage Alerts
Collapse Summary General Information
Company Onxeo S.A.
DescriptionRecombinant fusion protein derived from the pro-apoptotic human Fas ligand (FasL) protein
Molecular Target Fas receptor (CD95)
Mechanism of ActionFas receptor (CD95) agonist
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner

Oncology Venture ApS


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today